There are several therapeutic treatments in the works to treat Celiac Disease. According to research presented at the recent United European Gastroenterology Week (EUGW) held in October in Vienna, Austria, Alba/Teva’s Larazotide Acetate and Alvine/AbbVie’s Latiglutenase, may enter the marketing simultaneously.
Per article written by Abhilok Garg, Ph.D, an analyst with GlobalData, Larazotide Acetate is expected to launch in the US in 2018 and Latiglutenase to follow in 2019.
“Key opinion leaders interviewed by GlobalData from May to September 2014 suggested that both drugs are likely to be prescribed to celiac patients in combination, due to their differing, but complementary, mechanisms of action. GlobalData estimates that the potential introduction of Larazotide Acetate and Latiglutenase could drive celiac disease sales to reach approximately $551.1m by 2023 in the US and EU.”
To read the GlobalData summary article open HERE.
(you must register with GlobalData to read the full Expert Insight article)
